These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 10825081)

  • 1. Amphotericin B colloidal dispersion versus amphotericin B in the empirical treatment of fever and neutropenia.
    Roland WE
    Clin Infect Dis; 1999 Apr; 28(4):935-6. PubMed ID: 10825081
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia.
    White MH; Bowden RA; Sandler ES; Graham ML; Noskin GA; Wingard JR; Goldman M; van Burik JA; McCabe A; Lin JS; Gurwith M; Miller CB
    Clin Infect Dis; 1998 Aug; 27(2):296-302. PubMed ID: 9709879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia.
    Frothingham R
    Clin Infect Dis; 2002 Oct; 35(7):896-7; author reply 897-8. PubMed ID: 12228830
    [No Abstract]   [Full Text] [Related]  

  • 4. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
    Ullmann AJ; Heussel CP; Cornely OA
    N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12041526
    [No Abstract]   [Full Text] [Related]  

  • 5. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
    Apisarnthanarak A; Little JR; Tebas P
    N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12041527
    [No Abstract]   [Full Text] [Related]  

  • 6. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group.
    Wingard JR; White MH; Anaissie E; Raffalli J; Goodman J; Arrieta A;
    Clin Infect Dis; 2000 Nov; 31(5):1155-63. PubMed ID: 11073745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.
    Rijnders BJ; Cornelissen JJ; Slobbe L; Becker MJ; Doorduijn JK; Hop WC; Ruijgrok EJ; Löwenberg B; Vulto A; Lugtenburg PJ; de Marie S
    Clin Infect Dis; 2008 May; 46(9):1401-8. PubMed ID: 18419443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the current and future status of conventional amphotericin B?
    Kleinberg M
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antimicrobial therapy of neutropenia].
    Harten P; Euler HH
    Dtsch Med Wochenschr; 1998 Jan; 123(4):100-1. PubMed ID: 9487293
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia.
    Al-Badriyeh D; Liew D; Stewart K; Kong DC
    J Antimicrob Chemother; 2009 Jan; 63(1):197-208. PubMed ID: 19001450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
    Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
    Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empirical antifungal therapy for persistent fever in patients with neutropenia.
    Chandrasekar PH
    Clin Infect Dis; 2001 Jan; 32(2):320-1. PubMed ID: 11170928
    [No Abstract]   [Full Text] [Related]  

  • 13. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients.
    Bowden R; Chandrasekar P; White MH; Li X; Pietrelli L; Gurwith M; van Burik JA; Laverdiere M; Safrin S; Wingard JR
    Clin Infect Dis; 2002 Aug; 35(4):359-66. PubMed ID: 12145716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A benefit for renal function after early switch to liposomal amphotericin B from conventional formulation in empirical antifungal treatment.
    Isnard F; Tilleul P; Laporte JP; Chevallier P; Pigneux A; Lafuma A; Mahi L; Deray G
    Nephrol Dial Transplant; 2007 Oct; 22(10):3090-1. PubMed ID: 17595189
    [No Abstract]   [Full Text] [Related]  

  • 15. Withholding initial vancomycin in febrile neutropenia despite implanted catheters.
    Berger C; Kindli K; Niggli FK; Nadal D
    Eur J Pediatr; 2004 Jul; 163(7):422-3. PubMed ID: 15141312
    [No Abstract]   [Full Text] [Related]  

  • 16. Mortality rates in comparative trials of formulations of amphotericin B.
    Frothingham R
    Clin Infect Dis; 2001 Aug; 33(4):582-3. PubMed ID: 11462201
    [No Abstract]   [Full Text] [Related]  

  • 17. Lipid formulations of amphotericin B.
    Dix SP; Andriole VT
    Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
    Hamidah A; Lim YS; Zulkifli SZ; Zarina AL; Nordiah AJ; Jamal R
    Singapore Med J; 2007 Jul; 48(7):615-9. PubMed ID: 17609821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Febrile neutropenia in haematological malignancies.
    Sharma A; Lokeshwar N
    J Postgrad Med; 2005; 51 Suppl 1():S42-8. PubMed ID: 16519255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant?
    Hahn-Ast C; Glasmacher A; Arns A; Mühling A; Orlopp K; Marklein G; Von Lilienfeld-Toal M
    Infection; 2008 Feb; 36(1):54-8. PubMed ID: 18193385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.